Hepatitis C Trial, Recruiting NCT06870019 Sponsor: University of Southern California Condition: Hepatitis C
Back to Hepatitis C

Hepatitis C Trial, Recruiting

NCT06870019
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Hepatitis C
  • People who are currently experiencing homelessness without shelter (such as sleeping outside or in places not meant for housing) at the time the study begins
  • People who speak English or Spanish
  • People who are receiving care through a street medicine program (medical care provided directly to people experiencing homelessness in outdoor or community settings)
  • People whose Hepatitis C condition meets a specific set of treatment guidelines set by a major liver disease medical organisation, meaning their case is considered straightforward enough for a simplified treatment approach (confirm with trial site)

Who may not be able to join:

  • People who have previously received treatment for Hepatitis C
  • People who have a serious form of liver scarring called decompensated cirrhosis, or who test positive for Hepatitis B surface antigen (a marker indicating active Hepatitis B infection)
  • People who are currently pregnant, or who have been diagnosed with or are suspected of having liver cancer (hepatocellular carcinoma)
  • People who have previously had a liver transplant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Camilo Zaks, MD, University of Southern California, Keck School of Medicine of USC, Department of Family Medicine, USC Street Medicine

Phone: 626-457-4207

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
8 August 2025
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Medication Adherence Rate; Length of treatment course

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov